E-cadherin gene mutations are rare in adenocarcinomas of the oesophagus by Wijnhoven, B P L et al.
Cadherins are a family of Ca2+-dependent cell–cell adhesion mole-
cules. E-cadherin is a transmembrane protein with five tandemly
repeated extracellular domains and a cytoplasmic domain that
connects to the actin cytoskeleton through a complex with a-,
b- and g-catenins. E-cadherin is expressed on the cell surface in
most epithelial tissues and is important for establishing cell
polarity, maintaining epithelial integrity and cellular differentia-
tion (Takeichi, 1991). The potential for E-cadherin to serve as an
invasion or metastatic suppressor in epithelial tumorigenesis has
been elucidated from in vitro studies. E-cadherin-negative epithe-
lial cells grow invasive with a mesenchymal phenotype. After
transfection with E-cadherin cDNA, epithelial structure is restored
(Frixen et al, 1991; Vleminckx et al, 1991).
Consistent with this observation is a reduced or absent
E-cadherin expression in various epithelial cancers showing
invasive growth (Gabbert et al, 1996; Kuczyk et al, 1998; Sulzer
et al, 1998). Decreased expression of E-cadherin in Barrett’s
oesophagus, adenocarcinomas of the oesophagus and gastro-
oesophageal junction was found to be related with progression of
Barrett’s oesophagus to adenocarcinoma, tumour stage and lymph
node metastasis (Bongiorno et al, 1995; Bailey et al, 1998).
Furthermore, E-cadherin expression was an independent variable
predicting survival in patients after resection for adenocarcinomas
of the oesophagus (Krishnadath et al, 1997).
Loss of E-cadherin expression resulted in the transition from
well-differentiated adenoma to invasive carcinoma in mouse
pancreatic b-cell carcinogenesis (Perl et al, 1998). Inactivating
mutations in the E-cadherin gene have been described for various
tumours such as lobular breast cancer (in situ) and diffuse infil-
trating gastric cancer concomitant with loss of heterozygosity
(LOH) at the E-cadherin locus in E-cadherin-negative tumours
(Becker and Hofler, 1995; Berx et al, 1995, 1996; Vos et al, 1997).
Moreover, two recent studies showed that germline mutations in
the E-cadherin gene are associated with early onset familial gastric
cancer (Gayther et al, 1998; Guilford et al, 1998). Whether genetic
alterations in the E-cadherin gene play a role in the pathogenesis
of adenocarcinomas of the oesophagus and gastro-oesophageal
junction is not known. Therefore, we screened adenocarcinomas
of the oesophagus and gastro-oesophageal junction for E-cadherin
gene mutations and LOH.
METHODS
Tumour specimens
Fresh samples of adenocarcinomas of the distal oesophagus or
gastro-oesophageal junction were obtained from 45 resection
specimens. For analysis the tumour samples were microdissected
to enrich for cancer cells (> 75%). Nineteen tumours showed
microscopic evidence of surrounding intestinal metaplasia indica-
tive for Barrett’s carcinomas. Samples of tumour and normal
gastric epithelium or squamous epithelium of the oesophagus were
snap-frozen and stored in liquid nitrogen. Four lymph nodes
infiltrated by tumour were frozen as well.
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Cell lines and xenografts
In vitro cell lines form three adenocarcinomas JROECL19,
JROECL33, JROECL50 and one adenosquamous carcinoma
JROECL47 established by Rockett et al (1997) were obtained
from European Collection of Cell Cultures (ECACC). In vivo
xenografts were obtained after transplantation of tumour tissue to
female nude mice, 4–6 weeks of age. From three lymph node
metastases M2.1X1, M9X1, M4.1X2 and one primary tumour
P23X1, xenografts were obtained.
DNA preparation
DNA from cell lines was isolated according to standard pro-
cedures. Genomic DNA from xenografts and tumour samples and
normal tissue was isolated from consecutive 5-mm cryostat tissue
sections by overnight proteinase K incubation at 55°C followed by
phenol extraction and ethanol precipitation. DNA pellets were
dissolved in TE (10 mM Tris–HCl, pH 7.8; 1 mM EDTA). The
tumour tissue samples contained at least 75% tumour cells.
Analysis of the E-cadherin gene by PCR-SSCP
The entire open reading frame of the E-cadherin gene was
screened for mutations using 15 exon-spanning primer pairs (Berx
et al, 1995). Genomic DNA was used at 50–100 ng per 15 ml reac-
tion mixture containing 1.5 mM magnesium chloride, 0.02 mM
dATP, 0.2 mM dGTP, dTTP and dCTP each, 0.8 mCi a-32PdATP
(Amersham, Buckinghamshire, UK), 20 pmol of each primer and
0.2 U Taq polymerase (Promega, Madison, WI, USA). Each PCR
was overlaid with mineral oil. PCR was performed for 35 cycles
(denaturing at 95°C for 30 s, annealing at the appropriate tempera-
ture for 45 s and extension at 72°C for 1 min). A final extension
step was carried out at 72°C for 10 min. PCR products were
diluted 1:4 with a loading buffer (95% formamide, 10 mM EDTA
(pH 8.0), 0.025% bromophenol blue and 0.025% xylene cyanol),
denatured at 95°C for 4 min and snap-cooled on ice. Appropriate
aliquots of the radiolabelled PCR products were separated on a
non-denaturing polyacrylamide gel (6% polyacrylamide)
containing 10% glycerol and run at 7 W overnight at room temper-
ature in 1 ´ TBE running buffer. Gels were fixed in acetic acid
(10%), dried on blotting paper (Schleicher & Schuell, Dassel,
Germany) on a vacuum gel dryer and exposed to X-ray film
overnight at –70°C, using intensifying screens. DNA with aber-
rantly migrating PCR-SSCP fragments was reamplified and puri-
fied over QIAquick spin columns (Qiagen, Hilden, Germany),
cloned into a PGEM-T easy vector (Promega, Madison, WI,
USA), and sequenced with a-35SdATP according to the dideoxy
chain termination method. Electrophoresis of the sequenced
samples was carried out on an 8% denaturing polyacrylamide gel.
After fixation and drying, gels were exposed to X-ray film for 1–3
days at room temperature.
LOH determination
In 51 tumours LOH was determined with microsatellite markers
that map on 16q22.1 where the E-cadherin gene is located.
Markers tested were: D16S503, D16S265, D16S398 and
D16S512. Markers were tested on 100 ng of tumour and normal
DNA in a PCR reaction as described previously (Trapman et al,
1994). LOH was established by visual comparison of the intensity
of allelic bands obtained from tumour samples with those from
normal DNAs.
RESULTS
PCR-SSCP
All 16 exons and exon–intron boundaries of the E-cadherin gene
were analysed for genetic alterations in four cell lines, four
xenografts and 49 tumour samples (45 primary tumours and four
corresponding locoregional lymph node metastases). In total, 37
aberrant bands were detected throughout nine different amplicons.
Cell line, xenograft and tumour DNA with aberrant SSCP patterns
were compared with the amplification products of patient matched
non-tumorous DNA. In most tumours the aberrant SSCP pattern
was also present in the corresponding normal DNA (Figure 1). A
tumour-restricted mobility shift was found in cell lines JROECL47
and JROECL50 in amplicon 3 (Figure 1B). Upon sequencing a
one base-pair deletion in codon 120 (exon 3) was detected (Figure
2D and Table 1). Both cell lines were derived from the same
primary tumour (SJ Darnton, personal communication), in which
this mutation could not be detected. Sequence analysis of all the
other SSCP band shifts revealed eight known polymorphisms
and three new genetic alterations (Figure 2 A–C and Table 2).
Furthermore, upon sequencing of amplicon 16 a discrepancy with
the published sequence of intron 15 of the E-cadherin gene
deposited in EMBL/GenBank database libraries (accession no.
Z13009) was detected (5¢ intron15- … cttgag-3¢ exon 16).
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Figure 1 PCR-SSCP analysis of E-cadherin amplicons 2 (A), 3 (B) and 4/5
(C) from three oesophageal adenocarcinoma specimens and two cell lines
JROECL 47 and JROECL 50. Mobility shifts are identified by arrows.
C, control DNA; T, tumour DNA; N, corresponding non-tumourous DNALOH determination
In Figure 3 examples are presented of the analysis of the four
microsatellite loci in different tumour DNAs which showed allelic
loss. Of the 48 informative cases, 31 (65%) showed LOH of at
least one marker (Figure 4).
DISCUSSION
Reduced expression of E-cadherin is frequently seen in the
majority of adenocarcinomas of the oesophagus and gastro-
oesophageal junction with or without Barrett’s epithelium
(Bongiorno et al, 1995; Swami et al, 1995; Bailey et al, 1998).
However, E-cadherin immunoreactivity does not provide informa-
tion about the function of the protein and gene integrity. For
example, mutations in the E-cadherin gene leading to loss of
adhesive potential but with normal cellular localization of the
protein have been described (Becker et al, 1994; Oda et al,
1994). In this study we have analysed if genetic alterations in
the E-cadherin gene are involved in the reduced expression of
E-cadherin in adenocarcinomas of the oesophagus and gastro-
oesophageal junction. In an earlier study, eight out of 49 tumours
were analysed for expression of E-cadherin by means of immuno-
histochemistry. Seven out of eight of these adenocarcinomas
showed reduced expression for E-cadherin (Krishnadath et al,
1997).
In our series of 57 adenocarcinomas of the oesophagus only one
tumour restricted DNA alteration in the E-cadherin gene was
detected. In two cell lines JROECL 47 and JROECL 50, derived
from the same tumour, a one base-pair deletion was found leading
to a premature stopcodon resulting in a truncated protein lacking
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Table 1 Tumour-restricted mutation in cell lines JROECL 47 and
JROECL 50a
Amplicon Site Nucleotide change
3 Cdn 120 Deletion G: frameshift leading to
stopcodon at codon 214 in exon 5
aTwo cell lines derived from a primary tumour of one patient.
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Figure 2 Sequence analysis for the three tumours and cell line JROECL 47 with abnormally shifted PCR-SSCP bands as shown in Figure 1. Mutated
sequence (left) and wild-type sequence (right) are shown at the right of each figure. Base-pair alterations are indicated by arrows. Splice recognition site is
shown by the underlined characters in Figure 2C. For exon 2 (A) and exon 3 (B) we identified mis-sense mutations, also present in the normal control DNA of
these patients. For amplicon 4/5 a base-pair change was observed in intron 4 (C). One frameshift mutation caused by a 1-bp deletion was detected for exon 3
(D) in the two cell lines JROECL 47 and JROECL 50part of the extracellular binding region as well as the transmem-
brane and intracellular domain. So far, this mutation has not been
reported in the literature. Both cell lines still have a non-mutated
E-cadherin allele as demonstrated by the heterozygous exon 3
SSCP pattern indicating two different alleles. We were unable to
demonstrate this mutation in the primary tumour. Obviously, the
mutation was present in a minor subpopulation of the primary
tumour or has developed during establishment of both cell lines.
PCR-SSCP analysis is a robust mutation detection procedure
(Orita et al, 1989; Sheffield et al, 1993), indicated by the finding of
eight known polymorphisms and three not yet described DNA
alterations. However, we cannot rule out the possibility that muta-
tions remained undetected by this procedure. All three new DNA
alterations are also present in the patients’ normal DNA. Two of
these alterations lead to amino acid substitutions in the precursor
sequence of the E-cadherin gene. Recently, germline mutations
leading to truncated E-cadherin were identified in familial gastric
cancer in New Zealand and Europe (Gayther et al, 1998; Guilford
et al, 1998). Because no loss of the normal E-cadherin allele in
the tumours occurred we consider these DNA alterations as
polymorphisms. Furthermore, we have no evidence of a familial
predisposition to oesophageal cancer in any of our patients.
Allelic loss at the E-cadherin gene locus 16q22.1 has been
reported in 30–50% of breast, prostate and hepatocellular cancer
(Tamura, 1997). Our data show LOH of this locus in two-thirds of
the oesophageal adenocarcinomas. But the high percentage of
16q22.1 LOH without concomitant mutation of the remaining
E-cadherin gene might point to another tumour suppressor gene on
16q involved in the genesis or progression of oesophageal adeno-
carcinomas. We cannot rule out the possibility that homozygous
deletions are present in these carcinomas. Especially in DNA
derived from resection specimens homozygous deletions can
escape detection due to the contamination with non-tumorous
DNA. However, all exons could be amplified with DNA derived
from the cell lines and xenografts with exon spanning primers,
which makes it unlikely that homozygous deletions have occurred.
Alternatively, if the high frequency of LOH at 16q22.1 truly
reflects loss of one E-cadherin allele, this could point in the
E-cadherin gene mutation in adenocarcinoma of the oesophagus 1655
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Figure 3 Loss of heterozygosity in tumour 3 (D16S503), 10 (D16S265),
12 (D16S398) and 22 (D16S512). Loss of one allele is visible in the lane
containing tumour DNA (T) compared with the lane containing normal
DNA (N)
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Figure 4 Patterns of allelic loss in oesophageal adenocarcinomas at the
E-cadherin locus on chromosome 16q22.1. Closed rectangle, loss of
heterozygosity; white rectangle, heterozygosity retained; ni, non-informative;
MI, microsatellite instability; nd, no data obtainable. Note that 36M and 27M
are lymph node metastases from primary tumours 36 and 27 respectivelydirection of gene dosage effects as formerly proposed on the basis of
experimental studies (Vleminckx et al, 1991). However, a previous
study by Ilyas et al could not establish a correlation between allelic
loss and immunohistochemical E-cadherin expression in colorectal
cancers (Ilyas et al, 1997). Besides loss of one E-cadherin allele,
other mechanisms leading to down-regulation of E-cadherin in
oesophageal adenocarcinomas could also be involved.
Hypermethylation of the 5¢ CpG islands within the proximal
promoter region of the E-cadherin gene has been found respon-
sible for (temporary) down-regulation of E-cadherin in several
cancers (Graff et al, 1998; Hiraguri et al, 1998; Saito et al, 1998).
However, not only E-cadherin but also other members of the junc-
tional complex have been shown to play a role in tumorigenesis. In
several tumour cell lines showing impaired cell–cell adhesion and
reduced expression of E-cadherin, mutations in a-catenin and
b-catenin were identified (Shimoyama et al, 1992; Kawanishi et
al, 1995). A cytoplasmic and nuclear staining pattern of b-catenin
has been observed in adenocarcinomas of the oesophagus in cases
in which E-cadherin was reduced (Krishnadath et al, 1997; Bailey
et al, 1998). These tumours could harbour mutated b-catenin, as
was recently described for colon carcinomas and hepatocellular
carcinomas (de La Coste et al, 1998; Iwao et al, 1998). Whether or
not mutations in the catenins play a role in the pathogenesis of
oesophageal cancer is presently unknown.
In conclusion, our results show that E-cadherin gene mutations
are not involved in the subsequent progression of Barrett’s epithe-
lium to dysplasia and to adenocarcinoma of the oesophagus.
Whether LOH at the E-cadherin locus contributes to the hetero-
genous expression of E-cadherin remains to be determined.
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